Cervical cancer vaccine - Jiangsu Antae Biological Technology
Latest Information Update: 05 Aug 2016
At a glance
- Originator Jiangsu Antae Biological Technology
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Cervical cancer
Most Recent Events
- 03 Aug 2016 Clinical trials in Cervical cancer in China (Parenteral)
- 03 Aug 2016 Jiangsu Antae Biotechnology plans a phase III trial for Cervical cancer in China (ChiCTR-OIC-16008915)